'I got Tourette's syndrome after being bitten by a mosquito' - Manchester Evening News
Summary by Manchester Evening News
2 Articles
2 Articles
Phase 3 Data Shows Promise for First New Tourette Syndrome Treatment in 50 Years
Emalex Biosciences is advancing ecopipam, a first-in-class dopamine D1 receptor antagonist, as a novel treatment for Tourette syndrome. In February 2025, the company reported positive topline data from a phase 3 clinical trial involving over 200 pediatric patients, demonstrating statistically significant reductions in motor and vocal tics compared to placebo. Current Tourette treatments, primarily antipsychotics and alpha agonists, often have li…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium